Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Study Overview
=================
Brief Summary
-----------------
The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS Tablet FF in comparison to the tablet C at a dose of 5 mg after a standard breakfast in healthy male volunteers

Official Title
-----------------
Randomised, Open-label, Two-way Crossover Study in Male Healthy Volunteers to Investigate the Relative Bioavailability of BIIL 284 BS 5 mg Tablet FF in Comparison to Tablet C After Ingestion of a Standardised Meal

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: BIIL 284 BS Tablet FF
* Drug: BIIL 284 BS tablet C
* Other: standard breakfast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All participants are healthy males Age range from 21 to 50 years Broca-Index: within +- 20% of normal weight In accordance with Good Clinical Practice (GCP) and local legislation each volunteer is supposed to give their written informed consent prior to admission to the study Exclusion Criteria: Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of a drug with a long half-life (> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrollment in the study Use of any drugs which might influence the results of the trial (<= one week prior to administration or during the trial) Participation in another trial with an investigational drug (<= two months prior to administration or during the trial) Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) Inability to refrain from smoking on study days Alcohol abuse (> 60g/day) Drug abuse Blood donation (>= 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within the last week before the study ) Any laboratory value outside the reference range of clinical relevance

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BIIL 284 BS Tablet FF<br> | Drug: BIIL 284 BS Tablet FF<br> <br> Other: standard breakfast<br> <br> |
| Active Comparator: BIIL 284 BS tablet C<br> | Drug: BIIL 284 BS tablet C<br> <br> Other: standard breakfast<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) |  | up to 24 hours after drug administration | 
| Cmax (Maximum measured concentration of the analyte in plasma) |  | up to 24 hours after drug administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) |  | up to 24 hours after drug administration | 
| tmax (Time from dosing to the maximum concentration of the analyte in plasma) |  | up to 24 hours after drug administration | 
| Terminal rate constant in plasma |  | up to 24 hours after drug administration | 
| t½ (Terminal half-life of the analyte in plasma) |  | up to 24 hours after drug administration | 
| MRTtot (total mean residence time) |  | up to 24 hours after drug administration | 
| CL/F (Apparent clearance of the analyte in plasma following extravascular administration) |  | up to 24 hours after drug administration | 
| Vz/F (Apparent volume of distribution of the analyte during the terminal phase) |  | up to 24 hours after drug administration | 
| Number of subjects with adverse events |  | up to 8 days after last drug administration | 
| Number of subjects with clinically significant findings in vital functions | blood pressure, pulse rate, ECG | up to 8 days after last drug administration | 
| Number of subjects with clinically significant findings in laboratory tests |  | up to 8 days after last drug administration |